-
1
-
-
33745893883
-
Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy
-
Duvic M, Talpur R, Zhang C, Goy A, Richon V, Frankel SR (2005) Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J Clin Oncol 23 (16 S): abstract 6571
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 S
, pp. 6571
-
-
Duvic, M.1
Talpur, R.2
Zhang, C.3
Goy, A.4
Richon, V.5
Frankel, S.R.6
-
2
-
-
22944478042
-
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - An applicational observation
-
Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W (2005) Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. Br J Dermatol 153(1):167-173
-
(2005)
Br J Dermatol
, vol.153
, Issue.1
, pp. 167-173
-
-
Gellrich, S.1
Muche, J.M.2
Wilks, A.3
Jasch, K.C.4
Voit, C.5
Fischer, T.6
Audring, H.7
Sterry, W.8
-
3
-
-
0037967271
-
Phase II study of alemtuzumab (Campath-1H) in patients with advanced Mycosis fungoides/Sezary syndrome
-
Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A (2003) Phase II study of alemtuzumab (Campath-1H) in patients with advanced Mycosis fungoides/Sezary syndrome. Blood 101:4267
-
(2003)
Blood
, vol.101
, pp. 4267
-
-
Lundin, J.1
Hagberg, H.2
Repp, R.3
Cavallin-Stahl, E.4
Freden, S.5
Juliusson, G.6
Rosenblad, E.7
Tjonnfjord, G.8
Wiklund, T.9
Osterborg, A.10
-
4
-
-
0035863468
-
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
-
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388
-
(2001)
J Clin Oncol
, vol.19
, pp. 376-388
-
-
Olsen, E.1
Duvic, M.2
Frankel, A.3
Kim, Y.4
Martin, A.5
Vonderheid, E.6
Jegasothy, B.7
Wood, G.8
Gordon, M.9
Heald, P.10
Oseroff, A.11
Pinter-Brown, L.12
Bowen, G.13
Kuzel, T.14
Fivenson, D.15
Foss, F.16
Glode, M.17
Molina, A.18
Knobler, E.19
Stewart, S.20
Cooper, K.21
Stevens, S.22
Craig, F.23
Reuben, J.24
Bacha, P.25
Nichols, J.26
more..
-
5
-
-
0035525781
-
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
-
Piekarz RL, Robey R, Sandor V, Bakke S, Wilson, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865-2868
-
(2001)
Blood
, vol.98
, pp. 2865-2868
-
-
Piekarz, R.L.1
Robey, R.2
Sandor, V.3
Bakke, S.4
Wilson5
Dahmoush, L.6
Kingma, D.M.7
Turner, M.L.8
Altemus, R.9
Bates, S.E.10
-
6
-
-
20844443468
-
WHO-EORTC classification for cutaneous lymphomas
-
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785
-
(2005)
Blood
, vol.105
, pp. 3768-3785
-
-
Willemze, R.1
Jaffe, E.S.2
Burg, G.3
Cerroni, L.4
Berti, E.5
Swerdlow, S.H.6
Ralfkiaer, E.7
Chimenti, S.8
Diaz-Perez, J.L.9
Duncan, L.M.10
Grange, F.11
Harris, N.L.12
Kempf, W.13
Kerl, H.14
Kurrer, M.15
Knobler, R.16
Pimpinelli, N.17
Sander, C.18
Santucci, M.19
Sterry, W.20
Vermeer, M.H.21
Wechsler, J.22
Whittaker, S.23
Meijer, C.J.24
more..
-
7
-
-
0025336716
-
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells
-
Williams DP, Snider CE, Strom TB, Murphy JR (1990) Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885-11889
-
(1990)
J Biol Chem
, vol.265
, pp. 11885-11889
-
-
Williams, D.P.1
Snider, C.E.2
Strom, T.B.3
Murphy, J.R.4
|